StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for PDSB yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-18 | $1.33 | $1.18 | -11.28% | 1.1M |
| 05-19 | $1.17 | $1.00 | -14.53% | 1.7M |
| 05-20 | $1.02 | $1.03 | +0.98% | 0.8M |
| 05-21 | $1.04 | $1.16 | +11.54% | 0.8M |
| 05-22 | $1.19 | $1.20 | +0.84% | 1.2M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.